| 抗心绞痛药雷诺嗪的研究进展 |
| |
| 引用本文： | 陈頔,傅得兴,孙春华. 抗心绞痛药雷诺嗪的研究进展[J]. 中国新药杂志, 2008, 17(21) |
| |
| 作者姓名： | 陈頔 傅得兴 孙春华 |
| |
| 作者单位： | 1. 卫生部北京医院,北京大学第五临床医院药学部,北京,100730;北京大学医学部药学院药事管理与临床药学系,北京,100083
2. 卫生部北京医院,北京大学第五临床医院药学部,北京,100730 |
| |
| 摘 要： | 雷诺嗪(ranolazine)于2006年1月美国FDA批准上市,用于治疗慢性心绞痛.它是一种脂肪酸部分氧化抑制剂,通过改变葡萄糖和脂肪酸的代谢而发挥作用.临床研究表明,雷诺嗪单独使用或者与其他药物联合应用,可以安全有效地治疗慢性心绞痛.雷诺嗪常见的不良反应是眩晕、头痛、便秘、恶心.文中对雷诺嗪的药理作用、药动学、临床研究、药物相互作用、安全性评价等进行综述.
|
| 关 键 词： | 雷诺嗪 抗心绞痛药 慢性心绞痛 |
Advance in research of the antianginal agent ranolazine |
| |
| CHEN Di,FU De-xing,SUN Chun-hua. Advance in research of the antianginal agent ranolazine[J]. Chinese Journal of New Drugs, 2008, 17(21) |
| |
| Authors: | CHEN Di FU De-xing SUN Chun-hua |
| |
| Affiliation: | 1 Beijing Hospital;The Ministry of Public Health;The 5th Medical College of Peking University;Beijing 100730;China;2 Department of Pharmacy Administration and Clinical Pharmacy;School of Pharmaceutical Sciences;Peking University Health Science Center;Beijing 100083;China |
| |
| Abstract: | Ranolazine has been approved by the Food and Drug Administration of USA for the treatment of chronic angina pectoris in Jan,2006.Ranolazine is a new class of antianginal agents.It alters glucose and fatty acid metabolism.Clinical studies have demonstrated the efficacy and safety of ranolazine in the treatment of chronic angina pectoris,either as monotherapy or in combination with other antianginal agents.The common adverse effects of ranolazine include dizziness,headache,constipation,and nausea.This paper s... |
| |
| Keywords: | ranolazine antianginal agents chronic angina pectoris |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
